Jennifer Buell, Agenus president and COO (PR News Wire)

Bris­tol My­ers bets big on an­ti-TIG­IT bis­pe­cif­ic from Agenus in a part­ner­ship worth $1.5B+

The race to de­vel­op an­ti-TIG­IT drugs con­tin­ues to heat up, as a ma­jor I/O play­er part­ners with a biotech once rid­dled with set­backs.

Bris­tol My­ers Squibb is en­list­ing a pre­clin­i­cal pro­gram from Agenus to its pipeline, plunk­ing down $200 mil­lion up­front for a bis­pe­cif­ic an­ti­body that tar­gets both TIG­IT and an­oth­er undis­closed tar­get. The Big Phar­ma will sweet­en the pot with up to $1.36 bil­lion in po­ten­tial mile­stones, and Agenus will re­tain op­tions to de­vel­op the can­di­date in com­bi­na­tion with some of its oth­er pro­grams.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.